NEW YORK, NY--(Marketwire - Nov 16, 2011) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the District Court of Maryland on behalf of purchasers of Human Genome Sciences, Inc. ("HGS" or the "Company") (NASDAQ: [ HGSI ]) common stock between July 20, 2009 and November 11, 2010 including those who acquired shares in the July 28, 2009 public offering at $14 per share and in the December 2, 2009 public offering at $26.75.

For more information, click here: [ http://zlk.9nl.com/human-genome-hgsi ].

The complaint alleges that during the Class Period HGS, certain of the Company's directors and officers, and GlaxoSmithKline plc failed to disclose and/or misrepresented that there was an association of suicide with patients in the BENLYSTA clinical trials, the Company's product for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The complaint further alleges that during the Class Period, defendants sold more than 44.5 million shares of its common stock to the public in its July 28, 2009 and December 2, 2009 public offerings at artificially inflated prices.

Prior to a meeting of the FDA Advisory Committee Meeting, the FDA released its briefing documents and analysis regarding BENLYSTA that included information regarding the association of BENLYSTA with suicide in its clinical trials. In response to the news, HGS shares fell more than 10% to close at $23.60 per share on November 12, 2010.

If you suffered a loss in HGS stock you have until January 10, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://www.zlk.com/human-genome-sciences-hgs.html ].

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. Attorney advertising. Prior results do not guarantee similar outcomes.